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Abstract
The P2Y1 receptor responds to adenine nucleotides and is present in platelets, heart, smooth 
muscles prostate, ovary, and brain. A selective antagonist may be useful as an antithrombotic 
agent. We have analyzed the binding site of this G protein-coupled receptor using ligand design, 
site-directed mutagenesis, and homology modeling based on rhodopsin. We have designed and 
synthesized a series of deoxyadenosine 3′,5′-bisphosphate derivatives that act as antagonists, or, in 
some cases with small structural changes, as agonists or partial agonists. The 2-position 
accommodates Cl or thioethers, whereas the N6-position is limited to Me or Et. 2′-Substitution 
with OH or OMe increases agonist efficacy over 2′-H. Using molecular modeling of the binding 
site, the oxygen atoms of the ribose moiety were predicted to be non-essential, i.e. no specific H-
bonds with the receptor protein appear in the model. We have, therefore, substituted this moiety 
with carbocylics, smaller and larger rings, conformationally constrained rings, and acyclics, with 
retention of affinity for the receptor. With simplified pharmacophores we are exploring the steric 
and electronic requirements of the receptor binding site, and the structural basis of receptor 
activation.
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1. Introduction
Modulation of adenosine receptors (P1) and nucleotide (P2) receptors by selective agonists 
and antagonists [1,2] has the potential for the treatment of a wide range of diseases, 
including those of the cardiovascular, inflammatory, and central nervous systems. 
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Extracellular nucleotides, principally ATP, ADP, UTP, and UDP, act through two families 
of membrane-bound P2 receptors: P2Y subtypes, all of which are G protein-coupled 
receptors (GPCRs), generally coupled to phospholipase C (PLC); and P2X subtypes, ligand-
gated ion channels. Though the endogenous ligand for P2X receptors is generally ATP, P2Y 
receptors are activated by adenine and/or uracil nucleotides [2]. Agonists of P2 receptors are 
almost exclusively nucleosides and nucleotides, respectively, whereas antagonists of these 
receptors are structurally more diverse [1]. In comparison with the adenosine receptors, 
much less is known about the specific effects of P2 receptors, largely due to the lack of 
selective ligands. Within the family of P2Y receptors, we have focused on the P2Y1 
receptor, which was the first member to be cloned. The P2Y1 receptor is one of three P2 
receptors that occurs on the surface of platelets, and its activation has been proposed to play 
a role in platelet aggregation leading to thrombus formation. Thus, a selective P2Y1 
antagonist may prove useful as an antithrombotic agent.
We are currently designing and synthesizing novel ligands for both adenosine and P2 
receptors. Methods utilized in these recent investigations include: conformationally 
constraining the ribose, or ribose-like, moiety of nucleosides and nucleotides to freeze a 
conformation that may provide favorable affinity and/or selectivity at P1 and P2 receptors 
[3,4]; modifying known receptor antagonists [5-7]; use of a template approach based on the 
pyridine family for the design of novel adenosine antagonists [8]; and the screening of 
chemical libraries in conjunction with molecular modeling [9].
2. Results and discussion
2.1. Receptor modeling as a tool in ligand development
GPCRs represent a large family of many hundreds of gene products that share a common 
structural motif, i.e. they contain seven membrane-spanning helical domains (TMs) [10,11]. 
A large fraction of currently used pharmaceutical agents consist of synthetic agents that 
modulate the action of GPCRs, either as agonists or antagonists. Thus, it is of great interest 
to explore computationally the aspects of ligand binding common to these protein targets as 
an aid in the design of ligands. We have used mutagenesis and molecular modeling in 
conjunction with chemical modification of ligands to define putative binding sites. For small 
molecules in general, and for the P1 and P2 receptors specifically, these sites occur within a 
central cavity surrounded by the TM domains. Conformational considerations of both 
receptors and their ligands are important in structure-based drug design.
We have used alanine scanning mutagenesis of the human P2Y1 receptor to show the 
importance of specific residues in molecular recognition. Molecular modeling of both P1 
and P2Y receptors (using a rhodopsin template) and their docked ligands, based on 
mutagenesis results, have been carried out to interpret the findings and to suggest new 
ligands [12,13]. With simplified pharmacophores we are currently exploring the steric and 
electronic constraints of the receptor binding site, and the structural basis of receptor 
activation.
Molecular modeling of cloned P2Y1 receptor sequences has focused on both the seven TMs 
and the three extracellular loops (ELs). The features of the putative binding site identified 
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within the TM region were consistent with both mutagenesis results and known ligand 
specificities. To obtain an energetically refined 3D structure of the complex, we introduced a 
new approach, a ‘cross docking’ procedure [13], which simulated the reorganization of the 
native receptor induced by the ligand. In order to ascertain which residues of the human 
P2Y1 receptor are involved in ligand recognition, we mutated individual residues of both the 
TMs (3, 5, 6, and 7) and ELs 2 and 3. A cluster of positively charged amino acids, Lys and 
Arg residues near the exofacial side of TMs 3 and 7 and to a lesser extent TM6, putatively 
coordinates the phosphate moieties of nucleotide agonists and antagonists [14]. Two 
essential disulfide bridges in the extracellular domains were identified, and several charged 
residues in ELs 2 (E209) and 3 (R287) were shown to be critical for receptor activation. This 
suggested that the role of the ELs in ligand recognition was as important as that of the TMs 
[15]. Moreover, using both mutagenesis and molecular modeling [15], we have defined 
energetically favorable ‘meta-binding sites’ in the P2Y1 receptor, involving the critical 
residues of the ELs. At these nucleotide docking sites located distal to the principal TM site, 
a ligand may bind on its way to the principal TM binding site. These secondary binding sites 
may serve to guide the ligand in its approach to the TM binding site and reduce the energy 
barrier to complex formation. Further mutagenesis studies will be required to confirm this 
proposal. This phenomenon may prove to be general with the GPCR family, and may serve 
as the basis for modulation of the activity of endogenous ligands, perhaps using synthetic 
ligands that compete for binding preferentially at the ‘meta-binding sites’.
2.2. Ribose-modified nucleotide analogues
We have carried out extensive chemical probing of structure–activity relationships (SARs) 
for nucleotides acting at the P2Y1 receptor. Initially, we modified the native P2Y1 receptor 
ligands, and tested the analogues in a functional assay (activation of PLC) at the turkey 
erythrocyte P2Y1 receptor, which is very similar in structure to the human homologue. 
Using molecular modeling of the receptor binding site we predicted that there are no 
essential H-bonds predicted to form directly between the receptor protein and oxygen atoms 
of the ribose moiety of nucleotide ligands, and we have therefore removed both ether and 2′, 
and 3′ oxygen atoms of the ribose moiety. Based on the report by Boyer et al. [16], 
indicating that adenosine bisphosphates (at either 3′,5′ or 2′,5′ positions) were antagonists or 
partial agonists at the P2Y1 receptor, a series of deoxyadenosine 3′,5′-bisphosphate 
derivatives acting as selective P2Y1 antagonists was prepared (Fig. 1). Antagonism was 
defined as the ability to reverse completely the stimulation of PLC elicted by 30 nM 2-
methylthioadenosine-5′-diphosphate, an agonist of nanomolar potency. In some cases the 
related nucleotides could be interconverted between agonists (or partial agonists) and 
antagonists with small structural changes [17-19]. SAR analysis indicated that the 2-position 
accommodated Cl or thioethers, while the N6-position was limited to Me or Et. A 2′-
substitution (OH or ether) increased agonist efficacy over 2′-H. The analogue MRS 2179 
(2′-deoxy-N6-methyladenosine-3′,5′-bisphosphate), a more potent and competitive 
antagonist, contained an intact 2′-deoxyribose ring with adenine modifications. The N6-
methyl and 2-chloro modifications lead to lower agonist efficacy and higher affinity, 
respectively. MRS 2179 also antagonized rat P2X1 receptors in an electrophysiological 
model with an IC50 of 1.1 μM [20].
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Other modifications included substitution of the ribose moiety with carbocylics, smaller and 
larger rings, conformationally constrained rings, and acyclics, with retention of affinity for 
the receptor. Fig. 2 summarizes various types of ribose modification of nucleotide-based 
P2Y1 receptor antagonists. Ring expansion of the ribose in the 2-Cl-N6-Me series led to an 
anhydrohexitol derivative, MRS 2283, which displayed an IC50 of 0.566 μM, at the turkey 
erythrocyte P2Y1 receptor [19]. Ring contraction further emphasized the flexibility of 
substitution of the ribose moiety in these antagonists; the cyclobutyl derivative, MRS 2264, 
displayed an IC50 of 0.805 μM at the turkey P2Y1 receptor [19].
An acyclic modification of the ribose ring also pre-served affinity at the P2Y1 receptor. By 
analogy, acyclic modification of nucleosides has proven useful for antiviral agents. The 
antiviral compound pencyclovir corresponds formalistically to the structural ring opening of 
a carbocyclic guanosine derivative. Using a similar approach, we designed the acyclic 
adenosine bisphosphate, MRS 2286 (2-[2-(2-chloro-6-methylamino-purin-9 - yl) - ethyl] - 
propane - 1,3 - bisoxy(diammonium - phosphate)). This analogue corresponds to the 
carbocyclic antagonist analogue MRS 2267 (Fig. 2), in which the 2′-methylene has been 
omitted and a 2-Cl has been added (to increase affinity). MRS 2286 was an antagonist at the 
turkey P2Y1 receptor with an IC50 value of 0.84 μM, and no agonist activity was observed 
[21]. Furthermore, the compound was inactive at P2X1 receptors [20].
We recently discovered that one of the most generally useful modifications applicable to 
both P1 and P2 receptors is to lock the ribose sterically into a preferred conformation. 
Generally, the ribose rings of nucleosides and nucleotides may adopt a range of 
conformations as described by a ‘pseudorotational cycle’. The Northern ((N), 2′-exo, 3′-
endo) and Southern ((S), 2′-endo, 3′-exo) conformations are the most relevant to the 
biological activities observed for nucleosides and nucleotides in association with DNA, 
RNA, and various enzymes. Do the adenosine and P2 receptors prefer either one of these 
specific conformations of the ring?
In order to approach this question experimentally, we designed a series of P2 receptor 
ligands containing conformationally rigid ribose-like rings, based on carbocyclic rings. 
Conformational constraints were built into nucleoside and nucleotide ligands using the 
methanocarba approach, i.e. fused cyclopropyl and cyclopentyl rings in place of the ribose 
moiety. Rigid rings in the methanocarba series have defined a preference for the Northern 
(N) conformation of ribose at the P2Y1 receptor. MRS 2268, the (N)-methanocarba 
analogue of 2′-deoxyadenosine-3′,5′-bisphosphate, was a potent P2Y1 agonist (EC50 = 155 
nM), 86-fold more potent than the corresponding Southern (S) isomer, MRS 2266. 
However, the corresponding 2-Cl-N6-methyl-(N)-methanocarba analogue, MRS 2279 ((1R,
2S,4S,5S)-1-[(phosphato)methyl]-4-(2-chloro-6-methylaminopurin-9-yl) bicyclo[3.1.0]-
hexane-2-phosphate, Fig. 2), was a potent antagonist (IC50 = 52 nM). As with other ribose 
modifications, the presence of an N 6-Me group in (N)-methanocarba bisphosphate 
analogues transformed either a partial or full agonist into a pure antagonist, and the 2-chloro 
modification enhanced affinity.
In conclusion, we have demonstrated that the ribose moiety of P2Y1 agonists and 
antagonists is amenable to extensive modification. We have designed and tested both 
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conformationally rigid and structurally simplified antagonists, as well as agonist/antagonist 
pairs of compounds that differ in only subtle structural features. We are exploring the steric 
and electronic requirements of the receptor binding site, and the structural basis of receptor 
activation.
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Stereoview of hP2Y1 transmembrane helical bundle model viewed along the helical axes 
from the extracellular end (left) and perpendicular to the helical axes (right) after the ‘cross 
docking’ procedure for the P2Y1–ATP complex. The adenine moiety is the portion of the 
ligand situated closest to TM7.
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Modifications of nucleotide-based ligands in the development of P2Y1 receptor antagonists. 
IC50 values are for the inhibition of P2Y1-receptor stimulated PLC-activity in turkey 
erythrocyte membranes. PLC was stimulated by 30 nM 2-methylthioadenosine-5′-
diphosphate, a potent P2Y1 receptor agonist.
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